FR10C0025I2 - Protéines de fusion du récepteur de IL-1 utilisées comme antagonistes et méthodes d'utilisation et de fabrication - Google Patents

Protéines de fusion du récepteur de IL-1 utilisées comme antagonistes et méthodes d'utilisation et de fabrication

Info

Publication number
FR10C0025I2
FR10C0025I2 FR10C0025C FR10C0025C FR10C0025I2 FR 10C0025 I2 FR10C0025 I2 FR 10C0025I2 FR 10C0025 C FR10C0025 C FR 10C0025C FR 10C0025 C FR10C0025 C FR 10C0025C FR 10C0025 I2 FR10C0025 I2 FR 10C0025I2
Authority
FR
France
Prior art keywords
methods
antagonists
manufacture
fusion proteins
receptor fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR10C0025C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of FR10C0025I1 publication Critical patent/FR10C0025I1/fr
Application granted granted Critical
Publication of FR10C0025I2 publication Critical patent/FR10C0025I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR10C0025C 1998-09-25 2010-04-16 Protéines de fusion du récepteur de IL-1 utilisées comme antagonistes et méthodes d'utilisation et de fabrication Active FR10C0025I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10185898P 1998-09-25 1998-09-25
US09/313,942 US6472179B2 (en) 1998-09-25 1999-05-19 Receptor based antagonists and methods of making and using
EP99952942A EP1115876B1 (en) 1998-09-25 1999-09-22 Receptor based antagonists and methods of making and using

Publications (2)

Publication Number Publication Date
FR10C0025I1 FR10C0025I1 (enExample) 2010-05-21
FR10C0025I2 true FR10C0025I2 (fr) 2011-04-01

Family

ID=26798712

Family Applications (1)

Application Number Title Priority Date Filing Date
FR10C0025C Active FR10C0025I2 (fr) 1998-09-25 2010-04-16 Protéines de fusion du récepteur de IL-1 utilisées comme antagonistes et méthodes d'utilisation et de fabrication

Country Status (19)

Country Link
US (2) US6472179B2 (enExample)
EP (3) EP1229047B1 (enExample)
JP (1) JP3902728B2 (enExample)
CN (1) CN100345970C (enExample)
AT (2) ATE336583T1 (enExample)
AU (1) AU758970C (enExample)
BE (1) BE2010C021I2 (enExample)
CA (1) CA2345109C (enExample)
DE (3) DE69932832T2 (enExample)
DK (1) DK1229047T3 (enExample)
ES (2) ES2267300T3 (enExample)
FR (1) FR10C0025I2 (enExample)
HK (1) HK1045847B (enExample)
IL (2) IL142103A0 (enExample)
NO (2) NO329976B1 (enExample)
NZ (1) NZ510720A (enExample)
PL (1) PL201246B1 (enExample)
PT (1) PT1229047E (enExample)
WO (1) WO2000018932A2 (enExample)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
JP4271850B2 (ja) 1998-01-23 2009-06-03 イミュネックス・コーポレーション Ｉｌ−１８受容体
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
US7083949B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6927044B2 (en) * 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US20040120891A1 (en) * 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
MXPA02011682A (es) 2000-05-26 2003-05-14 Immunex Corp Uso de antagonistas de interleuquina-4 y composiciones de los mismos.
EP1290170A2 (en) * 2000-06-16 2003-03-12 Asterion Limited Binding agents: chimeric ligand/receptor proteins
ATE342980T1 (de) 2000-08-08 2006-11-15 Zymogenetics Inc Lösliche zcyctor 11 cytokinrezeptoren
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20050112616A1 (en) * 2001-12-10 2005-05-26 William Lee Functionalized materials and libraries thereof
US7795213B2 (en) * 2001-12-13 2010-09-14 Posco Methods of contacting β amyloid protein with VEGF
US6846520B2 (en) * 2002-01-17 2005-01-25 Canon Kabushiki Kaisha Epoxy resin composition, surface treatment method, liquid-jet recording head and liquid-jet recording apparatus
US6811780B2 (en) 2002-05-01 2004-11-02 Regeneron Pharmaceuticals, Inc. Methods of using cytokine antagonists to treat HIV infection and AIDS
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
NZ540555A (en) * 2002-11-15 2008-04-30 Genmab As Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders
US6919012B1 (en) 2003-03-25 2005-07-19 Olimex Group, Inc. Method of making a composite article comprising a ceramic coating
ES2327409T3 (es) 2003-03-26 2009-10-29 Apogenix Gmbh Proteinas de fusion fc mejoradas.
US20040224893A1 (en) * 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
WO2004098596A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising roflumilast and il-1 trap
CA2528569A1 (en) * 2003-06-11 2005-02-17 Wyeth Method for producing a polypeptide
EP3095793B1 (en) * 2003-07-28 2020-03-25 Genentech, Inc. Reducing protein a leaching during protein a affinity chromatography
JP2007503820A (ja) * 2003-09-05 2007-03-01 ナショナル・リサーチ・カウンシル・オブ・カナダ 細胞レセプタードメインを含むコイルドコイル融合タンパク質
WO2005047331A2 (en) 2003-11-07 2005-05-26 Immunex Corporation Antibodies that bind interleukin-4 receptor
ATE395358T1 (de) * 2004-02-27 2008-05-15 Regeneron Pharma Il-4/il-13-spezifische polypetide und deren therapeutische verwendung
JP5022216B2 (ja) 2004-06-04 2012-09-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 自己炎症性疾患を処置するためのｉｌ−１アンタゴニストを使用する方法
EP3059245B1 (en) 2004-07-23 2018-11-07 Acceleron Pharma Inc. Actrii receptor antagonistic antibodies
EP1778723B1 (en) * 2004-08-17 2012-11-14 Regeneron Pharmaceuticals, Inc. Il-1 antagonist formulations
DE602004014758D1 (de) * 2004-08-27 2008-08-14 Conaris Res Inst Ag Optimierte Nukleotidsequenzen die für sgp130 kodieren
US7786261B2 (en) * 2004-09-02 2010-08-31 National Research Council Of Canada Coiled-coil fusion proteins comprising cell receptor domains
DE602005021811D1 (de) * 2004-09-13 2010-07-22 Genzyme Corp Multimere konstrukte
RU2007117716A (ru) * 2004-10-12 2008-11-20 Ампротеин Корпорейшн (Us) Химерный белок
JP4898691B2 (ja) 2004-10-22 2012-03-21 ザイモジェネティクス， インコーポレイテッド 抗ｉｌ−２２ｒａ抗体および結合パートナー、ならびに炎症における使用法
JP2008527981A (ja) * 2005-01-25 2008-07-31 アポロ ライフ サイエンシズ リミテッド 治療目的および診断目的のためにパラメーターにより選択されたｇｍ−ｃｓｆ、ｉｌ−３、ｉｌ−４、ｉｌ−５、ならびにそのキメラ
ES2633574T3 (es) * 2005-03-25 2017-09-22 Regeneron Pharmaceuticals, Inc. Formulaciones de antagonistas de VEGF
US7732167B2 (en) * 2005-06-17 2010-06-08 Regeneron Pharmaceuticals, Inc. Interferon-α/β binding fusion proteins and therapeutic uses thereof
US7608430B2 (en) * 2005-07-08 2009-10-27 Regeneron Pharmaceuticals, Inc. Interferon-γ antagonists and therapeutic uses thereof
PT1912675E (pt) 2005-07-25 2014-05-09 Emergent Product Dev Seattle Moléculas de ligaçao especificas para cd37 e especificas para cd20
US7666622B2 (en) * 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US7889347B2 (en) 2005-11-21 2011-02-15 Plexera Llc Surface plasmon resonance spectrometer with an actuator driven angle scanning mechanism
MX2008006626A (es) * 2005-11-23 2008-09-24 Acceleron Pharma Inc Antagonistas de activin-actriia y usos para promover el crecimiento de huesos.
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US7463358B2 (en) 2005-12-06 2008-12-09 Lumera Corporation Highly stable surface plasmon resonance plates, microarrays, and methods
ES2395969T3 (es) 2006-03-24 2013-02-18 Merck Patent Gmbh Dominios de proteínas heterodiméricas genéticamente modificados
MX380352B (es) 2006-06-12 2025-03-12 Aptevo Res & Development Llc Proteinas de union multivalentes monocatenarias con funcion efectora.
PT2944306T (pt) 2006-06-16 2021-02-15 Regeneron Pharma Formulações antagonistas de vegf adequadas para administração intravitreal
PL1873166T3 (pl) * 2006-06-30 2011-03-31 Conaris Res Institute Ag Ulepszone dimery sgp 130Fc
US8106004B2 (en) * 2006-07-28 2012-01-31 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
JP5693004B2 (ja) 2006-07-28 2015-04-01 チルドレンズ メモリアル ホスピタル ヒト胚性幹細胞の微小環境を使用して腫瘍細胞の悪性度を抑制する方法
SI2124997T1 (sl) * 2006-10-20 2012-11-30 Regeneron Pharma Uporaba IL antagonista za zdravljenje putike inpsevdo putike
US7632490B2 (en) * 2006-10-20 2009-12-15 Regeneron Pharmaceuticals, Inc. Use of IL-1 antagonists to treat gout
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
JP5272735B2 (ja) * 2007-01-30 2013-08-28 国立大学法人 新潟大学 生物学的製剤
WO2008094708A2 (en) 2007-02-01 2008-08-07 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
TWI606062B (zh) 2007-02-09 2017-11-21 艾瑟勒朗法瑪公司 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途
TWI573802B (zh) 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
WO2008113185A1 (en) * 2007-03-19 2008-09-25 National Research Counsil Of Canada Antagonists of ligands and uses thereof
WO2009010539A2 (en) * 2007-07-19 2009-01-22 Ablynx. N.V. Receptor for interleukin-6 (il-6) from macaca fascicularis
WO2009038745A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
MX2010004892A (es) * 2007-10-31 2010-08-10 Scripps Research Inst Terapia de combinacion para tratar infecciones virales persistentes.
US8004669B1 (en) 2007-12-18 2011-08-23 Plexera Llc SPR apparatus with a high performance fluid delivery system
RS51975B (sr) 2008-04-11 2012-02-29 Emergent Product Development Seattle Llc. Cd37 imunoterapeutski proizvod i njegova kombinacija sa bifunkcionalnim hemoterapeutskim sredstvom
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
HRP20191109T1 (hr) 2008-08-14 2019-09-20 Acceleron Pharma Inc. Gdf klopke za uporabu u liječenju anemije
CA2737271C (en) * 2008-09-17 2020-06-23 National Research Council Of Canada Hetero-multivalent binding agents for members of the tgf.beta. superfamily
LT2370463T (lt) 2008-11-26 2016-12-12 Amgen Inc. Stabilizuotas aktivino iib receptoriaus variantas
AU2010258931B2 (en) 2009-06-08 2015-04-23 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
CA2781152A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
JP2014502260A (ja) 2010-11-08 2014-01-30 アクセルロン ファーマ， インコーポレイテッド Ａｃｔｒｉｉａ結合剤およびその使用
AU2012242666A1 (en) 2011-04-15 2013-11-28 Merck Patent Gmbh Anti- IL-1R1 inhibitors for use in cancer
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
EP2793925B1 (en) 2011-12-19 2019-03-20 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
ES2884095T3 (es) 2012-11-02 2021-12-10 Celgene Corp Antagonistas de activina-actrii y usos para el tratamiento de trastornos óseos y otros trastornos
CA2894219C (en) * 2012-12-10 2020-08-11 Vib Vzw Novel interleukin-33 inhibitors
EP3985024A1 (en) 2013-02-01 2022-04-20 Atara Biotherapeutics, Inc. Anti-activin-a compounds for the treatment of ovarian cancer
DK2956471T3 (da) 2013-02-15 2024-05-21 R Pharm Int Llc Il-1beta-hæmmersammensætning og anvendelse deraf
US12180264B2 (en) 2014-03-24 2024-12-31 R-Pharm Overseas, Inc. IL1-R1 derived inhibitor of IL-1β and use thereof
MA40008A (fr) 2014-06-13 2021-05-05 Acceleron Pharma Inc Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
PT3170005T (pt) 2014-07-18 2019-07-16 Sanofi Sa Método para a previsão do resultado de um tratamento com aflibercept de um paciente suspeito de sofrer de um cancro
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
CN107406491A (zh) 2014-12-01 2017-11-28 辉凌有限公司 选择性il‑6‑跨信号转导抑制剂组合物
SI3226888T1 (sl) 2014-12-01 2021-08-31 Ferring B.V. Dajanje selektivnega zaviralca signalizacije IL-6-trans
AU2015358469B2 (en) 2014-12-03 2021-05-27 Acceleron Pharma Inc. Activin-ActRII antagonists and uses for treating anemia
GB201503453D0 (en) 2015-03-01 2015-04-15 Jain Arjun Endothelin-1"sponge"
CA2984010A1 (en) * 2015-05-12 2016-11-17 Regeneron Pharmaceuticals, Inc. Multimeric protein purity determination
BR112018005573A2 (pt) 2015-09-21 2019-01-22 Aptevo Research And Development Llc ?polipeptídeos de ligação a cd3?
CN118307682A (zh) 2016-09-27 2024-07-09 埃皮辛特瑞柯斯公司 免疫调节性融合蛋白
AU2018254542B2 (en) * 2017-04-21 2022-12-22 Elanco Us Inc. IL4/IL13 receptor molecule for veterinary use
CA3077223A1 (en) 2017-09-27 2019-04-04 Epicentrx, Inc. Immunomodulatory fusion proteins
JP7319992B2 (ja) 2018-03-09 2023-08-02 アジェナス インコーポレイテッド 抗ｃｄ７３抗体およびそれらの使用方法
CA3105879A1 (en) 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
CN110950965B (zh) * 2018-09-26 2021-10-15 重庆精准生物技术有限公司 抗人cd123的嵌合抗原受体及其应用
KR20230092978A (ko) 2020-10-19 2023-06-26 조에티스 서비시즈 엘엘씨 개 및 고양이 온코스타틴 m 수용체 베타에 대한 항체 및 이의 용도

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
AU651596B2 (en) * 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
DE10075010I2 (de) * 1990-06-28 2004-01-29 Hoechst Ag Fusionsproteine mit immunglobulinanteilen, ihre Herstellung und Verwendung.
EP0533006A1 (en) * 1991-09-18 1993-03-24 F.Hoffmann-La Roche & Co. Aktiengesellschaft Chimaeric interleukin 5-receptor/immunoglobulin polypeptides
JP3122139B2 (ja) * 1991-10-15 2001-01-09 マラーキー，ミッシェル，エフ． 後期段階炎症反応の治療用組成物
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
WO1993018047A1 (en) * 1992-03-09 1993-09-16 Ludwig Institute For Cancer Research Nucleic acid sequences coding for or complementary to nucleic acid sequences coding for interleukin 9 receptor
WO1993019163A1 (en) * 1992-03-18 1993-09-30 Yeda Research And Development Co, Ltd. Chimeric receptor genes and cells transformed therewith
US8211422B2 (en) * 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
NZ251820A (en) * 1992-03-30 1996-07-26 Immunex Corp Fusion proteins with tnf-r (tumour necrosis factor-receptor) peptide linked to another tnf-r or an il-1r (interleukin-1-receptor) peptide
JP3255699B2 (ja) 1992-04-23 2002-02-12 味の素株式会社 ヒトＩＬ−２レセプターγ鎖分子
US5747292A (en) * 1993-04-06 1998-05-05 Fred Hutchinson Cancer Research Center Chimeric cytokine receptors in lymphocytes
EP0716703A1 (en) * 1993-09-03 1996-06-19 PRENDERGAST, Kenneth, Francis Glycophorin binding protein (gbp130) fusion compositions
AU701623B2 (en) * 1993-10-14 1999-02-04 President And Fellows Of Harvard College Method of inducing and maintaining neuronal cells
US5470952A (en) 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
IL114825A0 (en) * 1994-08-04 1995-12-08 Regeneron Pharma Rtk/cytokine receptor chimeras
AU3830895A (en) 1994-10-07 1996-05-02 Amgen Boulder Inc. Dimeric il-4 inhibitors
US5741899A (en) * 1995-02-02 1998-04-21 Cell Genesys, Inc. Chimeric receptors comprising janus kinase for regulating cellular pro liferation
US5837816A (en) * 1995-05-10 1998-11-17 Chiron Corporation Interleukin-2 receptor subunit ectodomain fusion protein comprising a leucine zipper domain
GB9526131D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US5776731A (en) * 1996-02-21 1998-07-07 Immunex Corporation DNA encoding type-I interleukin-I receptor-like protein designated 2F1
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
AU3668897A (en) * 1996-07-17 1998-02-09 University Of Medicine And Dentistry Of New Jersey Chimeric receptors for jak-stat signal transduction
WO1998008969A1 (en) * 1996-08-26 1998-03-05 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
GB9625899D0 (en) 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
JP4271850B2 (ja) * 1998-01-23 2009-06-03 イミュネックス・コーポレーション Ｉｌ−１８受容体

Also Published As

Publication number Publication date
ES2267300T3 (es) 2007-03-01
DE69922269D1 (de) 2004-12-30
IL142103A (en) 2007-07-04
HK1035377A1 (en) 2001-11-23
EP1229047A2 (en) 2002-08-07
NO2011003I2 (enExample) 2011-04-11
EP1405915A1 (en) 2004-04-07
NO20011513L (no) 2001-05-25
AU758970C (en) 2007-05-03
DK1229047T3 (da) 2005-02-21
WO2000018932A3 (en) 2000-11-02
EP1229047A3 (en) 2002-10-02
JP2002525119A (ja) 2002-08-13
HK1045847A1 (en) 2002-12-13
BE2010C021I2 (enExample) 2018-12-04
NO329976B1 (no) 2011-01-31
DE122010000023I1 (de) 2012-04-26
US20020164690A1 (en) 2002-11-07
EP1115876B1 (en) 2006-08-16
CN100345970C (zh) 2007-10-31
AU6499499A (en) 2000-04-17
NO20011513D0 (no) 2001-03-23
CN1357049A (zh) 2002-07-03
US6472179B2 (en) 2002-10-29
FR10C0025I1 (enExample) 2010-05-21
CA2345109A1 (en) 2000-04-06
IL142103A0 (en) 2002-03-10
JP3902728B2 (ja) 2007-04-11
PL348529A1 (en) 2002-06-03
NZ510720A (en) 2003-11-28
NO2011003I1 (no) 2011-05-02
PT1229047E (pt) 2005-03-31
US20020012962A1 (en) 2002-01-31
DE122010000023I2 (de) 2012-04-26
DE69932832D1 (de) 2006-09-28
ES2233733T3 (es) 2005-06-16
DE69922269T2 (de) 2005-12-01
WO2000018932A2 (en) 2000-04-06
DE69932832T2 (de) 2007-02-08
AU758970B2 (en) 2003-04-03
CA2345109C (en) 2012-12-18
ATE283365T1 (de) 2004-12-15
ATE336583T1 (de) 2006-09-15
HK1045847B (en) 2005-03-24
EP1115876A2 (en) 2001-07-18
WO2000018932A9 (en) 2000-08-31
PL201246B1 (pl) 2009-03-31
EP1229047B1 (en) 2004-11-24

Similar Documents

Publication Publication Date Title
FR10C0025I2 (fr) Protéines de fusion du récepteur de IL-1 utilisées comme antagonistes et méthodes d'utilisation et de fabrication
IL168050A (en) Il-1 receptor based antagonists and methods of making them and reagents for use therein
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
EA200600126A1 (ru) Антитела против tnf, композиции, способы и применения
TR200001861T2 (tr) Yeni G protein birleştirilmiş alıcı
WO2004003147A3 (en) Cngh0004 polypeptides, antibodies, compositions, methods and uses
CY1112101T1 (el) Νευροτροφικοι παραγοντες
ATE541930T1 (de) Il-17-homologe polypeptide und ihre therapeutische verwendung
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
WO2004043403A3 (en) Synthetic single domain polypeptides mimicking apolipoprotein e and methods of use
DE69737476D1 (de) Neuer galaninrezeptor
ATE374819T1 (de) Antagonistischer antikörper gegen pro842
WO2000006733A3 (en) T cell receptor proteins, nucleic acid molecules, and uses thereof
SE9804274D0 (sv) Novel receptor
DE60236143D1 (de) Gewebe transglutaminase
TR200100219T2 (tr) IL-8 Reseptörü Antagonistleri
SE9902763D0 (sv) Novel receptor
WO2003046125A3 (en) Hin-2 nucleic acid molecules, proteins, antibodies, homologues, receptors, and uses thereof
SE0002364D0 (sv) Growth Factors
ID27964A (id) Turuna-azabisikloheptana n-tersubstitusi, pembuatan dan penggunaannya